Of the several mechanisms of action of metformin in treating cancer, the activation of adenosine 5′-monophosphate-activated protein kinase (AMPK) and the inhibition of mTOR activity are considered the main pathways against RCC [19]. This evidence concerns the gene MTOR and renal cell carcinoma.